Citations

Clear

846 citation(s) found for "Li, Min".

Abstract 166: Spatial subtypes and cellular interactions of cancer-associated fibroblasts revealed by single-cell spatial omics
Zhang, Yuanyuan , Liu, Yang , Wang, Ruiping , Pei, Guangsheng , Cho, Kyung Serk , Basi, Akshay , Rajapakshe, Kimal , Chu, Yanshuo , Jiang, Jiahui , Zhang, Daiwei , Yan, Xinmiao , Guerrero, Paola A. , Li, Mingyao , Hwang, Tae Hyun , Futreal, P. Andrew , Soto, Luisa M. Solis , Kadara, Humam , Liu, Yunhe , Sinjab, Ansam F. , Min, Jimin , Han, Guangchun , Paradiso, Francesca , Dai, Enyu , Burks, Jared K , Serrano, Alejandra G. , Ajani, Jaffer A. , Jazaeri, Amir Anthony , Maitra, Anirban , Wang, Linghua

Mayo Clinic

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 166-166

10.1158/1538-7445.am2025-166 Get It

Abstract Background: Cancer-associated fibroblasts (CAFs) are a highly diverse cell population that plays a crucial role in shaping the tumor microenvironment (TME). Their spatial interactions within the TME remain to be systematically characterized, and the factors driving their phenotypic heterogeneity are not yet fully understood. Recent advancements in single-cell spatial transcriptomics technologies and cell segmentation approaches enable the precise measurement of thousands of transcripts at subcellular resolution. Combined with innovative bioinformatics, these advancements have unlocked unprecedented opportunities for in-depth characterization of CAFs and their interactions within the TME. Methods: We conducted a comprehensive spatial transcriptomic analysis of CAFs across 8 cancer types, using the CosMx and MERSCOPE platforms to profile nearly 6 million cells as part of our discovery cohorts. We developed a novel computational method to spatially cluster CAF subpopulations and defined four distinct spatial CAF subtypes. We further examined their phenotypic differences, spatial niche organization, and interactions with neighboring cells. Additionally, we investigated the influence of CAF subtypes on immune cell phenotypes and infiltration levels. To validate our findings, we employed multiple spatial platforms, including Visium, Xenium, COMET, CODEX, and IMC, to ensure reproducibility across diverse technologies. Moreover, we performed correlative studies in large-cohorts with rich clinical data to evaluate the clinical significance of these CAF subtypes. Results: Our approach provided an unprecedented high-resolution examination of the spatial phenotypes of CAFs in large, complex tissues, uncovering novel insights. We comprehensively characterized CAFs across various solid tumor types and identified four conserved spatial CAF subtypes. These subtypes are characterized by distinct cell organizational patterns, neighboring cell compositions, interaction networks, and transcriptomic features. Moreover, they demonstrate significant correlations with the abundance, distribution, and phenotypes of tumor-infiltrating immune cells, as well as associations with tumor histopathological features and clinical outcomes. Conclusions: Our study provides a pan-cancer, high-resolution characterization of CAF spatial organization and interactions in solid tumors and identified conserved spatial CAF subtypes linked to distinct organizational patterns. Our findings reveal that the transcriptomic states and phenotypes of CAFs are significantly shaped by their interactions with neighboring cancer and immune cells. Beyond offering novel insights into the spatial heterogeneity of CAFs, this work paves the way for developing strategies to effectively target and modulate CAFs for therapeutic benefit. Citation Format: Yunhe Liu, Ansam Sinjab, Jimin Min, Guangchun Han, Francesca Paradiso, Yuanyuan Zhang, Yang Liu, Ruiping Wang, Guangsheng Pei, Kyung Serk Cho, Enyu Dai, Akshay Basi, Jared K. Burks, Kimal I. Rajapakshe, Yanshuo Chu, Jiahui Jiang, Daiwei Zhang, Xinmiao Yan, Paola A. Guerrero, Alejandra Serrano, Mingyao Li, Tae Hyun Hwang, Andrew Futreal, Jaffer A. Ajani, Luisa M Solis Soto, Amir A. Jazaeri, Humam Kadara, Anirban Maitra, Linghua Wang. Spatial subtypes and cellular interactions of cancer-associated fibroblasts revealed by single-cell spatial omics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 166.
Abstract 3583: The Breast Cancer Risk Prediction Project: a resource of 1.8 million women with diverse backgrounds from 20 prospective cohorts to improve breast cancer risk prediction and advance breast cancer epidemiology
Kraft, Peter, O’Meara, Ellen S. , Rohan, Thomas, Neuhouser, Marian L, Vachon, Celine M, Haiman, Christopher, White, Emily , Lee, I‐Min , Gaudet, Mia M. , Chatterjee, Nilanjan , Freeman, Laura E. Beane , Palmer, Julie R. , Genkinger, Jeanine M. , Lacey, James V. , Teras, Lauren R. , Visvanathan, Kala , Milne, Roger L. , Chen, Yu , Eliassen, A. Heather , Kitahara, Cari M. , O’Brien, Katie M. , Anderson, Garnet L. , Campbell, Archie I , Fortner, Renée T. , Lagerros, Ylva Trolle , Sandin, Sven , García‐Closas, Montserrat

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3583-3583

10.1158/1538-7445.am2025-3583 Get It

Abstract Breast cancer risk assessment tools are widely used in clinical practice to guide decisions regarding screening timing and modality, lifestyle interventions, genetic testing, preventive therapy, and risk-reducing surgery. Although a number of tools designed for the general population are used in practice, they face a series of challenges including: (i) modest discriminatory ability due to lack of a unified model that flexibly incorporates a comprehensive set of risk factors; (ii) inability to produce subtype-specific risk estimates, relevant for tailoring screening and/or preventive strategies (e.g. prophylactic endocrine therapy that is effective only for hormone receptor positive tumors); (iii) lack of data from diverse populations to build models that work well for all women; and, (iv) scarcity of opportunities for comparative validation of different models. The Breast Cancer Risk Prediction Project (BCRPP), a collaboration currently including 20 prospective cohorts from the National Cancer Institute’s Cohort Consortium, is addressing these challenges by harmonizing, sharing, and analyzing data on over 1.8 million women, over 115, 000 of whom have developed breast cancer. The BCRPP is developing a comprehensive tool that will predict breast cancer risk, overall and by subtypes, across major racial and ethnic groups in the United States. This tool incorporates known and emerging risk factors (e.g. reproductive history, anthropometry, smoking, alcohol intake, medication use, mammography, family history, and measured genotypes). In parallel to model building and validation efforts, BCRPP investigators are developing privacy-preserving web and mobile interfaces to deliver the risk tools to patients and clinicians. Here we present descriptive data on participating cohorts (e.g. dates of enrollment, ages at enrollment, length of follow up, numbers of cases by subtype), summarize missing data patterns and our approach to model development and validation that accounts for heterogeneity in missingness patterns across cohorts, and describe data governance procedures and data sharing infrastructure (including pooled and federated analyses, to account for policy limitations on sharing individual data). Descriptive information and procedures for requesting and accessing data are available via the BCRPP data platform (https://epidataplatforms.cancer.gov/bcrpp/). Although originally assembled for risk model development, these data on a large and diverse sample of women with extensive harmonized risk factors and covariates can be a resource to address other outstanding questions in breast cancer epidemiology across time, the lifecourse, and diverse populations. Citation Format: Peter Kraft, Laura Beane-Freeman, Julie Palmer, Ellen O'Meara, Jeanine Genkinger, James Lacey, Thomas Rohan, Lauren Teras, Marian L. Neuhouser, Kala Visvanathan, Celine Vachon, Roger Milne, Christopher Haiman, Yu Chen, Heather Eliassen, Cari Kitahara, Katie O'Brien, Emily White, Garnet Anderson, I-Min Lee, Archie Campbell, Renee Fortner, Ylva Lagerros, Sven Sandin, Mia Gaudet, Montserrat Garcia-Closas, Nilanjan Chatterjee. The Breast Cancer Risk Prediction Project: a resource of 1.8 million women with diverse backgrounds from 20 prospective cohorts to improve breast cancer risk prediction and advance breast cancer epidemiology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3583.
Abstract P1062: Pre-Pandemic Thrombo-inflammatory Biomarkers and Risk of Severe Covid-19: the Collaborative Cohort of Cohorts for Covid-19 Research (C4R)
Cushman, Mary , Choi, Yuni , Reiner, Alex P. , Mukaz, Debora Kamin , Xanthakis, Vanessa, Johnson, Andrew D. , Umans, Jason G. , Kandula, Namratha R. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Jacobs, David R. , Demmer, Ryan T. , Tracy, Russell P. , Olson, Nels C. , Doyle, Margaret F. , Raffield, Laura M. , Min, Yuan‐I , Vasan, Ramachandran S. , Xanthakis, Vanessa , Make, Barry J. , Regan, Elizabeth Anne , Bowler, Russell P. , Thyagarajan, Bharat

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p1062 Get It

Background: Thrombo-inflammation is a hallmark of acute Covid-19, with higher thrombo-inflammatory markers during infection associated with adverse outcomes. We hypothesized that higher pre-pandemic biomarkers, reflecting a higher thrombo-inflammatory setpoint, might identify people at greater risk of severe manifestations of Covid-19. Hypothesis: Pre-pandemic inflammation markers are associated with risk of hospitalized or fatal (hereafter, “severe”) Covid-19 in a multi-ethnic US sample. Methods: From 2020-2023, C4R harmonized pre-pandemic measures and ascertained Covid-19 across 14 longstanding cohort studies. In 12 cohorts, we assessed biomarker data and covariates from the study visit closest to the pandemic for 6 analytes shown in the Table. HRs of severe Covid-19 by pre-pandemic biomarkers were estimated using cause-specific Cox regression, treating non-severe Covid-19 as a competing risk, and adjusting for pre-pandemic sociodemographic and clinical characteristics. Results: Biomarkers were measured a mean of 20 years before the pandemic with different sample sizes for each (Table footnote). Mean age at the start of the pandemic was in the 60s or 70s depending on the biomarker. The most represented race or ethnic groups were White and Black. The largest sample was for C-reactive protein, and there were 1,001 severe Covid-19 cases among 38,784 participants. In the adjusted models, considered individually, higher CRP, leukocyte count, factor VIII and fibrinogen, but not other markers, were associated with greater risk of severe Covid-19 (Table).Associations were robust across subgroups and time since biomarker measurement (example for C-reactive protein in Figure). Conclusions: In this prospective multi-study analysis of a multi-ethnic population, higher basal levels of thrombo-inflammation markers were associated with greater risk of severe Covid-19. Since we considered non-severe Covid-19 as a competing risk, associations may reflect factors related to progression to more serious Covid-19 illness.
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study
Balte, Pallavi , Sun, Yifei , Allen, Nori, Arynchyn, Alexander , Bowler, Russell P. , Elkind, Mitchell S, Garcia‐Bedoya, Olga , Garudadri, Suresh , Hansel, Nadia N. , Hermann, E.A. , Hoffman, Eric A. , Kaplan, Robert C. , Laine, Andrew F. , Lynch, David A. , Matsushita, Kunihiro , McKleroy, William , Naik, Sneha N. , O'Driscoll, O., Rusk, A.M., Salvatore, Mary , Smith, Benjamin M. , Sotres‐Alvarez, Daniela , Umans, Jason G. , Washko, George R. , Woodruff, Prescott G. , Ortega, Victor E. , Oelsner, Elizabeth C. , Balte, Pallavi P , Bowler, Russell P , San Jose Estepar, Raul , Hoffman, Eric A , Humphries, Stephen M , Krishnan, Jerry A , Podolanczuk, Anna J , Rusk, Annie, Wenzel, Sally E , Oelsner, Elizabeth C , Kim, John S. , Allen, Nori, Angelini, Elsa D. , Barr, R. Graham , Blaha, Michael Joseph , Carr, J. Jeffrey , Cole, Shelley A. , Couper, David , Demmer, Ryan T. , Doyle, Margaret F. , Estépar, Raúl San Jośe , Humphries, Stephen M. , Hunninghake, Gary M. , Lee, Joyce , Make, Barry J. , Min, Yuan‐I , O’Connor, George T. , Oren, Eyal , Podolanczuk, Anna J. , Post, Wendy S. , Pottinger, Tess D. , Regan, Elizabeth Anne , Schwartz, David A. , Vasan, Ramachandran S. , Wenzel, Sally E. , Xanthakis, Vanessa

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 16, 2025 | Volume: 211 | Issue: 7 | Pages: 1196-1210

10.1164/rccm.202408-1656oc | PMID 40238945 Get It

Abstract Rationale Increased risk of coronavirus disease (COVID-19) hospitalization and death has been reported among patients with clinical lung disease. Objectives To test the association of objective measures of prepandemic lung function and structure with COVID-19 outcomes in U.S. adults. Methods Prepandemic obstruction (FEV1/FVC < 0.70) and restriction (FEV1/FVC ⩾ 0.7, FVC < 80%) were defined based on the most recent spirometry exam conducted in 11 prospective U.S. general population–based cohorts. Severe obstruction was classified by FEV1 < 50%. Percentage emphysema, percentage high-attenuation areas, and interstitial lung abnormalities were defined on computed tomography in a subset. Incident COVID-19 was ascertained via questionnaires, serosurvey, and medical records from 2020 to 2023 and classified as severe (hospitalized or fatal) or nonsevere. Cause-specific hazard models were adjusted for sociodemographics, anthropometry, smoking, comorbidities, and COVID-19 vaccination status. Measurements and Main Results Among 29,323 participants (mean age, 67 yr), there were 748 severe incident COVID-19 cases over median follow-up of 17.3 months from March 1, 2020. Greater hazards of severe COVID-19 were associated with severe obstruction (vs. normal; adjusted hazard ratio [aHR], 2.11; 95% confidence interval [CI], 1.02–1.27), restriction (vs. normal; aHR, 1.40; 95% CI, 1.12–1.76), and percentage emphysema (highest vs. lowest quartile; aHR, 1.64; 95% CI, 1.03–2.61), but not greater high-attenuation areas or interstitial lung abnormalities. COVID-19 vaccination provided greater absolute risk reduction in these groups. Results were similar in participants without smoking, obesity, or clinical cardiopulmonary disease. Conclusions Prepandemic severe spirometric obstruction, spirometric restriction, and greater percentage emphysema lung on computed tomography were associated with risk of severe COVID-19. These findings support enhanced COVID-19 risk mitigation for individuals with impaired lung health and warrant further mechanistic studies on interactions of lung function, structure, and vulnerability to acute respiratory illnesses.
Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis
Sun, Bo , Fernandes, Dominique , Soltys, John , Paneva, Sofija , Harrison, Ruby , Harrison, Anna, Makuch, Mateusz , Fichtner, Miriam L. , Donat, Robert F. , Akdeniz, Deniz, Bayuangga, Halwan Fuad , Im, Min Gyu , Williams, Robyn , VASCONCELOS, ANA RAQUEL GOUVEIA , Thomsen, Selina, Fower, Andrew , Sun, Ruyue, Fox, Hannah , Mgbachi, Victor , Davies, Alexander J. , Tseng, Mandy , Handel, Adam E. , Kelly, Mark , Zhao, Meng , Bancroft, James , Bashford-Rogers, Rachael , Pluvinage, John V. , Dandekar, Ravi , Alvarenga, Bonny D. , Dustin, Lynn B. , Rinaldi, Simon , Owens, Raymond J. , Anthony, Daniel C. , Bennett, David , Davis, Simon J. , Wilson, Michael R. , O’Connor, Kevin C. , Carvalho, Ana Luı́sa , Irani, Sarosh R. , Kienzler, Anne-Kathrin , Paneva, Sofija , Harrison, Ruby , Harrison, Anna L , Fichtner, Miriam L , Bayuangga, Halwan , Im, Min Gyu , Vasconcelos, Ana , Fower, Andrew , Fox, Hannah , Davies, Alexander , Tseng, Mandy , Handel, Adam , Kelly, Mark , Zhao, Meng , Bancroft, James , Pluvinage, John V , Dandekar, Ravi , Alvarenga, Bonny D , Dustin, Lynn B , Rinaldi, Simon , Owens, Ray , Anthony, Daniel , Bennett, David L , Davis, Simon J , Wilson, Michael R , O'Connor, Kevin C , Carvalho, Ana Luisa , Irani, Sarosh R , Sun, Bo , Williams, Robyn L , Ramanathan, Sudarshini , Sun, Ruyue, Waters, Patrick

Mayo Clinic

Science Advances | April 16, 2025 | Volume: 11 | Issue: 16 | Pages: No page available

10.1126/sciadv.adr9986 | PMID 40238887 Get It

Autoantibody-mediated diseases targeting one autoantigen provide a unique opportunity to comprehensively understand the development of disease-causing B cells and autoantibodies. Convention suggests that such autoreactivities are generated during germinal center reactions. Here, we explore earlier immune checkpoints, focusing on patients with contactin-associated protein-like 2 (CASPR2)–autoantibody encephalitis. In both disease and health, high (~0.5%) frequencies of unmutated CASPR2-reactive naïve B cells were identified. By contrast, CASPR2-reactive memory B cells were exclusive to patients, and their B cell receptors demonstrated affinity-enhancing somatic mutations with pathogenic effects in neuronal cultures and mice. The unmutated, precursor memory B cell receptors showed a distinctive balance between strong CASPR2 reactivity and very limited binding across the remaining human proteome. Our results identify permissive central tolerance, defective peripheral tolerance, and autoantigen-specific tolerance thresholds in humans as sequential steps that license CASPR2-directed pathology. By leveraging the basic immunobiology, we rationally direct tolerance-restoring approaches, with an experimental paradigm applicable across autoimmunity.
Identifying an Optimal Cut-off Value and if Sex Differences Exist in Nigrostriatal Dopamine Transporter Binding of 123I-FP-CIT SPECT in Autopsy Confirmed Lewy Body Disease and/or Alzheimer’s Disease (P10-3.002)
Miyagawa, Toji , Przybelski, Scott A. , Vernon, Cynthia, Min, Hoon‐Ki , Forsberg, Leah K. , Fields, Julie A. , Graff-Radford, Jonathan, Savica, Rodolfo , Reichard, Ross R., Parisi, Joseph, Day, Gregory S. , Graff‐Radford, Neill R. , Jain, Manoj , Lowe, Val J. , Min, Hoon-Ki Paul , Day, Gregory S , McCarter, Stuart J. , Ferman, Tanis J. , Ramanan, Vijay K. , Graff‐Radford, Jonathan , Jones, David T. , Nguyen, Aivi T. , Dickson, Dennis W. , Murray, Melissa E. , Louis, Erik K. St. , Kantarci, Kejal , Boeve, Bradley F.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211473 Get It

Targeting IGF1 ‐Induced Cellular Senescence to Rejuvenate Hair Follicle Aging
Wang, Yang , Yang, Jian , Luo, Yue , Zhao, Zhiqiang , Yuan, Yawen, Li, Juan , Liu, Yang, Xu, Xiaoke , Lan, Yuankunyu, Zou, Juan , Li, Qintong , Pan, Yang , Yang, Yuanhan, Xiong, Muzhao, Li, Jinsong , Li, Weiyuxin , Cao, Yang , Zhu, Yi , Yang, Jian , Zhu, Yi , Xiao, Zhi‐Xiong Jim , Liu, Yang, Yi, Yong , Lan, Yuankunyu, Zou, Juan, Wang, Liang , Yang, Yuanhan, Wu, Min Cong , Zhang, Yujun

Mayo Clinic

Aging Cell | March 31, 2025 | Volume: 24 | Issue: 7 | Pages: No page available

10.1111/acel.70053 | PMID 40159808 Get It

ABSTRACT The insulin‐like growth factor‐1 (IGF‐1) signaling pathway is known as a potent aging modifier, disruption of which consistently associates with lifespan extension across diverse species. Despite this established association, the mechanisms by which IGF‐1 signaling modulates organ aging remain poorly understood. In this study, we assessed age‐related changes in IGF‐1 expression across multiple organs in mice and identified a more prominent increase in skin IGF‐1 levels with aging—a phenomenon also observed in human skin. To explore the consequences of elevated IGF‐1, we developed transgenic mice ectopically expressing human IGF‐1 in the epidermis, driven by the bovine keratin 5 promoter (IGF‐1 Tg). These mice exhibited premature aging of hair follicles, as evidenced by accelerated hair graying and loss. Single‐cell RNA sequencing analyses of dorsal skin highlighted an upsurge in cellular senescence markers and the senescence‐associated secretory phenotype (SASP) in hair follicle stem cells (HFSCs), alongside a decline in hair growth and HFSC exhaustion. Our findings indicate that excessive IGF‐1 triggers HFSC senescence, thereby disrupting hair follicle homeostasis. Remarkably, interventions in IGF‐1 signaling via downstream mechanisms—specifically blocking Ac‐p53 activation via SIRT1 overexpression or senolytic treatment for senescent cell clearance, or reducing IGF‐1 through dietary restriction—significantly reduced senescence markers, mitigated premature hair follicle aging phenotypes, and restored the stem cell pool. Our findings provide fundamental insights into the biological processes of hair aging and highlight the therapeutic promise of targeted interventions to rejuvenate aged HFSCs and promote hair follicle health.
Measurable Residual Disease Analysis by Flow Cytometry: Assay Validation and Characterization of 385 Consecutive Cases of Acute Myeloid Leukemia
Jum’ah, Husam , Otteson, Gregory E., Timm, Michael, Weybright, Matthew J. , Shi, Min , Horna, Pedro , Reichard, Kaaren K. , Olteanu, Horatiu , Jum'ah, Husam A, Timm, Michael M, Olteanu, Horatiu , Shi, Min , Horna, Pedro , Jevremović, Dragan

Mayo Clinic

Cancers | March 31, 2025 | Volume: 17 | Issue: 7 | Pages: 1155

10.3390/cancers17071155 | PMID 40227672 Get It

Background/Objectives: Acute myeloid leukemia (AML) is a biologically heterogeneous malignancy with a variable prognosis. Despite many patients achieving complete remission, relapse remains common, underscoring the need for effective prognostic markers. Measurable residual disease (MRD) has emerged as a critical prognostic indicator, associated with higher relapse risk and shorter survival. This study reports on our initial experience of MRD detection by flow cytometry in 385 bone marrow samples from 126 AML patients. Methods: The flow cytometry MRD assay, validated according to stringent consensus recommendations, consists of a 3-tube, 10-color panel incorporating a broad spectrum of lineage differentiation markers. Analytical specificity, sensitivity, precision, and reproducibility were evaluated, demonstrating the assay’s robustness. Results: The results reveal distinct immunophenotypic aberrancies in all AML cases, with consistent identification of aberrant immunophenotypes in follow-up specimens. AML MRD was detected in 32 out of 126 patients (25%) and in 77 out of 385 analyses (20%), with a median aberrant blast percentage of 1.87% (range, 0.01–12). A change in immunophenotype was documented in 21% of the MRD-positive cases. MRD positivity detected in the first sample studied was associated with reduced overall survival (HR: 5.153; p < 0.0001). Conclusions: Our findings support the integration of flow cytometric MRD analysis into routine clinical practice to enhance risk stratification and treatment planning for AML patients, as currently recommended by professional guidelines.
Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure
Ghazal, Rachad , Wang, Min , Liu, Duan , Tschumperlin, Daniel J. , Pereira, Naveen L. , Ghazal, Rachad , Wang, Min , Liu, Duan

Mayo Clinic

Circulation Research | March 27, 2025 | Volume: 136 | Issue: 7 | Pages: 773-802

10.1161/circresaha.124.325402 | PMID 40146800 Get It

Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics technologies have begun revolutionizing our understanding of the molecular mechanisms driving cardiac fibrosis and are providing unprecedented insights into its heterogeneity and progression. This review provides a comprehensive analysis of how techniques—encompassing genomics, epigenomics, transcriptomics, proteomics, and metabolomics—are providing insight into our understanding of cardiac fibrosis. Genomic studies have identified novel genetic variants and regulatory networks associated with fibrosis susceptibility and progression, and single-cell transcriptomics has unveiled distinct cardiac fibroblast subpopulations with unique molecular signatures. Epigenomic profiling has revealed dynamic chromatin modifications controlling fibroblast activation states, and proteomic analyses have identified novel biomarkers and potential therapeutic targets. Metabolomic studies have uncovered important alterations in cardiac energetics and substrate utilization during fibrotic remodeling. The integration of these multi-omic data sets has led to the identification of previously unrecognized pathogenic mechanisms and potential therapeutic targets, including cell-type-specific interventions and metabolic modulators. We discuss how these advances are driving the development of precision medicine approaches for cardiac fibrosis while highlighting current challenges and future directions in translating multi-omic insights into effective therapeutic strategies. This review provides a systems-level perspective on cardiac fibrosis that may inform the development of more effective, personalized therapeutic approaches for heart failure and related cardiovascular diseases.